Loading the company…
Loading the company…
㈜제네톡스
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-10-11 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Gangwon, founded in 2018. Industry: Bio & Pharma. Revenue for 2025 was ₩20.2bn. It has 89 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Qualified”.
Loading…
Latest filing 2025-01-13 · latest registration 2025-09-30 · newest first
본 발명은 보툴리눔 독소의 고효율 정제를 위한 최적화된 클로스트리디움 보툴리눔 균주 배양 및 정제 방법에 관한 것으로, 보툴리눔 균주의 배양 및 보툴리눔 독소 정제방법을 최적화하여 고효율, 고순도의 보툴리눔 독소를 수득할 수 있는 배양 및 정제방법에 관한 것이다. 본 발명은 배양공정 단계에서 종배양 배지의 혐기 방치 단계 추가 및 종배양과 본배양에 동일한 배양 배지를 사용함으로써 배양 단계에서 세포 증식율과 독소 생성량을 높였으며, 제조공정 단계에서 원심분리필터를 사용한 버퍼 교환방식으로 정제 단계를 단순화하여 전체 공정시간을 단축하면서도 고순도의 보툴리눔 독소를 얻을 수 있는 방법이다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 1 of 1 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 22.6 | 20.2 |
| Cost of sales | 7.0 | 7.4 |
| Gross profit (loss) | 15.6 | 12.7 |
| Selling, general and administrative expenses | 8.3 | 7.1 |
| Operating income (loss) | 7.3 | 5.6 |
| Non-operating income | 0.6 | 0.2 |
| Other gains | 0.1 | 0.0 |
| Finance income | 0.0 | 0.1 |
| Other | 0.5 | 0.2 |
| Non-operating expenses | 0.9 | 1.0 |
| Other losses | 0.0 | 0.0 |
| Finance costs | 0.6 | 0.4 |
| Other | 0.3 | 0.6 |
| Profit (loss) before tax | 7.0 | 4.8 |
| Income tax expense | — | 0.1 |
| Net income (loss) | 7.0 | 4.8 |
Revenue ₩20.2bn, down 10.7% YoY.
Operating margin 27.7% (prior 32.4%).
Net income ₩4.8bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-06